Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw

  • Kang, Mong-Hun (Department of Oral and Maxillofacial Surgery, Korea University Anam Hospital) ;
  • Lee, Dong-Keon (Department of Oral and Maxillofacial Surgery, Korea University Anam Hospital) ;
  • Kim, Chang-Woo (Department of Oral and Maxillofacial Surgery, Korea University Anam Hospital) ;
  • Song, In-Seok (Department of Oral and Maxillofacial Surgery, Korea University Anam Hospital) ;
  • Jun, Sang-Ho (Department of Oral and Maxillofacial Surgery, Korea University Anam Hospital)
  • Received : 2018.07.10
  • Accepted : 2018.09.04
  • Published : 2018.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: The purpose of this study was to investigate the demographic and clinical characteristics of patients with medication-related osteonecrosis of the jaw (MRONJ) and to elucidate factors affecting recurrence in surgical treatment. Materials and Methods: A total of 51 patients who were diagnosed with MRONJ were analyzed according to demographic and clinical features and treatment results through a retrospective chart review from 2013 to 2017 in the Department of Oral and Maxillofacial Surgery, Korea University Anam Hospital, Seoul in Korea. Results: Alendronate composed the majority of medication doses (55.6%), followed by ibandronate (20.0%), risedronate (15.6%), and zoledronate (6.7%). Forty patients (88.9%) were given oral medication, and five patients (11.1%) were intravenously treated, and the mean duration of medication use was $61.1{\pm}42.9$ months. A total of 10 patients (22.2%) had a drug holiday before MRONJ-induced dental treatment lasting an average of $6.8{\pm}7.0$ months. MRONJ occurred 2.7 times more in the mandible, with 41 cases (73.2%) occurring in the mandible and 15 cases (26.8%) occurring in the maxilla, and the prevalence of affected posterior parts (premolar-molar) was six times greater than that of the anterior parts (incisor-canine) (48 cases vs 8 cases, 85.7% vs 14.3%). The most common dental cause of MRONJ was tooth extraction (69.6%). Regarding recurrence, there was no statistical difference in recurrence rate according to either site or stage. However, recurrence occurred in 4 out of 34 cases (11.8%) in the primary closure group and 9 out of 20 cases (45.0%) in the secondary healing group, and there was a statistical difference with respect to closure technique. Conclusion: The identified risk factors in patients taking bone resorption inhibitors can aid dental clinicians in ensuring prevention and proper treatment of MRONJ.

Keywords

References

  1. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-56. https://doi.org/10.1016/j.joms.2014.04.031
  2. Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 2003;19:395-414. https://doi.org/10.1016/S0749-0690(02)00069-1
  3. Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993;95:297-304. https://doi.org/10.1016/0002-9343(93)90282-T
  4. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-200. https://doi.org/10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0
  5. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22. https://doi.org/10.1056/NEJMoa067312
  6. Lipton A, Fizazi K, Stopeck AT, Henry DH, Smith MR, Shore N, et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer 2016;53:75-83. https://doi.org/10.1016/j.ejca.2015.09.011
  7. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmeno- pausal women with osteoporosis. N Engl J Med 2009;361:756-65. https://doi.org/10.1056/NEJMoa0809493
  8. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011;48:677-92. https://doi.org/10.1016/j.bone.2010.11.020
  9. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009;20:137-45. https://doi.org/10.1093/annonc/mdn526
  10. Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G, et al. Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci 2011;1218:62-79. https://doi.org/10.1111/j.1749-6632.2010.05835.x
  11. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41:318-20. https://doi.org/10.1016/j.bone.2007.04.196
  12. Lopez-Jornet P, Camacho-Alonso F, Martinez-Canovas A, Molina-Minano F, Gomez-Garcia F, Vicente-Ortega V. Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws. J Oral Maxillofac Surg 2011;69:2488-93. https://doi.org/10.1016/j.joms.2011.02.059
  13. Hoefert S, Schmitz I, Tannapfel A, Eufinger H. Importance of mi- crocracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and nonsymptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig 2010;14:271-84. https://doi.org/10.1007/s00784-009-0300-6
  14. Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY. Medi- cation related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab 2015;22:151-65. https://doi.org/10.11005/jbm.2015.22.4.151
  15. Tsao C, Darby I, Ebeling PR, Walsh K, O'Brien-Simpson N, Reynolds E, et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg 2013;71:1360-6. https://doi.org/10.1016/j.joms.2013.02.016
  16. Peer A, Khamaisi M. Diabetes as a risk factor for medication-related osteonecrosis of the jaw. J Dent Res 2015;94:252-60. https://doi.org/10.1177/0022034514560768
  17. McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis 2018;24:527-36. https://doi.org/10.1111/odi.12708
  18. Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg 2009;67:943-50. https://doi.org/10.1016/j.joms.2008.12.057
  19. Scoletta M, Arduino PG, Dalmasso P, Broccoletti R, Mozzati M. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:46-53. https://doi.org/10.1016/j.tripleo.2010.02.020
  20. Mücke T, Koschinski J, Deppe H, Wagenpfeil S, Pautke C, Mitchell DA, et al. Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J Cancer Res Clin Oncol 2011;137:907-13. https://doi.org/10.1007/s00432-010-0953-1
  21. Klingelhöffer C, Zeman F, Meier J, Reichert TE, Ettl T. Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws. J Craniomaxillofac Surg 2016;44:1694-9. https://doi.org/10.1016/j.jcms.2016.08.001
  22. Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg 2012;41:1397-403. https://doi.org/10.1016/j.ijom.2012.06.020
  23. Etminan M, Aminzadeh K, Matthew IR, Brophy JM. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol 2008;35:691-5.
  24. Khan AA, Rios LP, Sandor GK, Khan N, Peters E, Rahman MO, et al. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 2011;38:1396-402. https://doi.org/10.3899/jrheum.100221
  25. Ulmner M, Jarnbring F, Törring O. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg 2014;72:76-82. https://doi.org/10.1016/j.joms.2013.06.221
  26. Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc 2010;141:1365-70. https://doi.org/10.14219/jada.archive.2010.0082
  27. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012;27:694-701. https://doi.org/10.1002/jbmr.1479
  28. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Sto- peck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012;23:1341-7. https://doi.org/10.1093/annonc/mdr435
  29. Jang HW, Kim JW, Cha IH. Development of animal model for Bisphosphonates-related osteonecrosis of the jaw (BRONJ). Maxillofac Plast Reconstr Surg 2015;37:18. https://doi.org/10.1186/s40902-015-0020-6
  30. Kim HJ, Park TJ, Ahn KM. Bisphosphonate-related osteonecrosis of the jaw in metastatic breast cancer patients: a review of 25 cases. Maxillofac Plast Reconstr Surg 2016;38:6. https://doi.org/10.1186/s40902-016-0052-6
  31. Choi WS, Lee JI, Yoon HJ, Min CK, Lee SH. Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma. Maxillofac Plast Reconstr Surg 2017;39:1. https://doi.org/10.1186/s40902-016-0099-4
  32. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009;27:5356-62. https://doi.org/10.1200/JCO.2009.21.9584
  33. Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 2009;112:605-9. https://doi.org/10.1016/j.ygyno.2008.11.029
  34. Phal PM, Myall RW, Assael LA, Weissman JL. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol 2007;28:1139-45. https://doi.org/10.3174/ajnr.A0518
  35. Ida M, Watanabe H, Tetsumura A, Kurabayashi T. CT findings as a significant predictive factor for the curability of mandibular osteomyelitis: multivariate analysis. Dentomaxillofac Radiol 2005;34:86-90. https://doi.org/10.1259/dmfr/23641620
  36. Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2011;142:1243-51. https://doi.org/10.14219/jada.archive.2011.0108
  37. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015;30:3-23. https://doi.org/10.1002/jbmr.2405
  38. Damm DD, Jones DM. Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. Gen Dent 2013;61:33-8.
  39. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-41. https://doi.org/10.1016/j.tripleo.2006.06.004
  40. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci 2011;1218:38-46. https://doi.org/10.1111/j.1749-6632.2010.05768.x
  41. Lee HK, Seo MH, Pang KM, Song SI, Lee JK. Comparative study on surgical and conservative management of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in disease stage 2. J Korean Assoc Maxillofac Plast Reconstr Surg 2013;35:302-9.
  42. Lopes RN, Rabelo GD, Rocha AC, Carvalho PA, Alves FA. Surgical therapy for bisphosphonate-related osteonecrosis of the jaw: six-year experience of a single institution. J Oral Maxillofac Surg 2015;73:1288-95. https://doi.org/10.1016/j.joms.2015.01.008
  43. Stockmann P, Burger M, von Wilmowsky C, Ebker T, Lutz R, Bau- ersachs A, et al. The outcome after surgical therapy of bisphosphonate-associated osteonecrosis of the jaw--results of a clinical case series with an average follow-up of 20 months. Clin Oral Investig 2014;18:1299-304.
  44. Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, et al. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 2010;18:449-60. https://doi.org/10.1007/s00520-009-0688-1
  45. Shin SH, Kim KH, Choi NR, Kim IR, Park BS, Kim YD, et al. Effect of low-level laser therapy on bisphosphonate-treated osteoblasts. Maxillofac Plast Reconstr Surg 2016;38:48. https://doi.org/10.1186/s40902-016-0095-8
  46. Kim HC, Song JM, Kim CJ, Yoon SY, Kim IR, Park BS, et al. Combined effect of bisphosphonate and recombinant human bone morphogenetic protein 2 on bone healing of rat calvarial defects. Maxillofac Plast Reconstr Surg 2015;37:16. https://doi.org/10.1186/s40902-015-0015-3
  47. Kim HY, Lee SJ, Kim SM, Myoung H, Hwang SJ, Choi JY, et al. Extensive surgical procedures result in better treatment outcomes for bisphosphonate-related osteonecrosis of the jaw in patients with osteoporosis. J Oral Maxillofac Surg 2017;75:1404-13. https://doi.org/10.1016/j.joms.2016.12.014
  48. Wilde F, Heufelder M, Winter K, Hendricks J, Frerich B, Schramm A, et al. The role of surgical therapy in the management of intrave- nous bisphosphonates-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111:153-63. https://doi.org/10.1016/j.tripleo.2010.04.015
  49. Gallego L, Junquera L, Pelaz A, Hernando J, Megías J. The use of pedicled buccal fat pad combined with sequestrectomy in bisphosphonate-related osteonecrosis of the maxilla. Med Oral Patol Oral Cir Bucal 2012;17:e236-41.

Cited by

  1. Risk factors for developing osteonecrosis of jaw in advanced cancer patients underwent zoledronic acid treatment vol.15, pp.30, 2019, https://doi.org/10.2217/fon-2019-0352
  2. Analysis of Factors Associated with the Postoperative Healing of Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis vol.10, pp.16, 2021, https://doi.org/10.3390/jcm10163651
  3. Medication-Related Osteonecrosis of the Jaw-A Continuing Issue vol.11, pp.17, 2018, https://doi.org/10.3390/app11177781
  4. Investigation of the Effectiveness of Surgical Treatment on Maxillary Medication-Related Osteonecrosis of the Jaw: A Literature Review vol.10, pp.19, 2021, https://doi.org/10.3390/jcm10194480
  5. CD34 and CD105 Microvessels in Resected Bone Specimen May Implicate Wound Healing in MRONJ vol.18, pp.21, 2018, https://doi.org/10.3390/ijerph182111362